基于钾离子竞争性酸抑制剂的四联方案根除幽门螺杆菌疗效的研究  

Research on the efficacy of quadruple regimen based on potassium ion competitive acid blocker in eradicating Helicobacter pylori

作　　者：刘锦红[1] 李鹏[1] 谭亮[1] 王志红[1] 苏畅 李盛 LIU Jinhong;LI Peng;TAN Liang;WANG Zhihong;SU Chang;LI Sheng(Medical College of Shaoguan University,Guangdong,Shaoguan 512005,China;Department of Gastroenterology,Yuebei People’s Hospital Affiliated to Medical College of Shantou University,Guangdong,Shaoguan 512026,China)

机构地区：[1]韶关学院医学院,广东韶关512005 [2]汕头大学医学院附属粤北人民医院消化内科,广东韶关512026

出　　处：《中国医药科学》2025年第5期84-88,共5页China Medicine And Pharmacy

基　　金：2023年韶关市支持科研工作者项目(230331158038531);韶关市卫生健康科研项目(Y23137);韶关学院医学院科研规划项目(EKY202205)。

摘　　要：目的评估基于钾离子竞争性酸抑制剂(P-CAB)的四联根除幽门螺杆菌(Hp)方案的有效性和安全性。方法通过回顾性分析2022年7—12月在粤北人民医院消化内科就诊采用四联方案根除Hp感染的436例患者,分为P-CAB的四联方案组(P-CAB组)196例和含质子泵抑制剂(PPIs)的四联方案组(PPI组)240例,从病历资料搜集相关信息,比较分析两组患者完成疗程后4周以上Hp的成功根除率和不良事件发生率。结果P-CAB组和PPI组患者年龄、性别、体重指数、吸烟例数、饮酒例数、合并疾病、谷丙转氨酶及血肌酐水平等差异无统计学意义(P>0.05)。P-CAB组Hp成功根除率高于PPI组(91.3%vs.82.9%,P<0.05);P-CAB组临床有效率高于PPI组(93.1%vs.84.4%,P<0.05);两组不良事件发生率比较,差异无统计学意义(14.8%vs.18.8%,P>0.05)。结论基于P-CAB的四联根除Hp方案成功率和临床有效率优于PPI四联方案,安全性相当。Objective To evaluate the effectiveness and safety of quadruple regimen based on potassium ion competitive acid blocker(P-CAB)in eradicating Helicobacter pylori(Hp).Methods A total of 436 patients who underwent quadruple regimen in eradicating Hp infection and were admitted to the Department of Gastroenterology of Yuebei People’s Hospital from July to December 2022 were retrospectively analyzed.They were divided into the P-CAB group(n=196,treated by quadruple regimen containing P-CAB)and the PPI group(n=240,treated by quadruple regimen containing proton pump inhibitors,PPIs).Relevant information was collected from medical records,and the successful eradication rate and the incidence of adverse events of Hp more than 4 weeks after the completion of the course of treatment were compared and analyzed between the two groups of patients.Results There were no statistically significant differences in age,gender,body mass index,number of smokers,number of drinkers,comorbidities,alanine aminotransferase and serum creatinine between the P-CAB group and the PPI group(P>0.05).The successful eradication rate of Hp in the P-CAB group was 91.3%,higher than 82.9%in the PPI group,with statistically significant difference(P<0.05).The clinical effective rate in the P-CAB group was 93.1%,higher than 84.4%in the PPI group,with statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse events(14.8%vs.18.8%,P>0.05).Conclusion The success rate and clinical effective rate of quadruple regimen containing P-CAB in eradicating Hp are superior to the quadruple regimen containing PPIs,and the safety is equivalent.

关 键 词：钾离子竞争性酸抑制剂 质子泵抑制剂 幽门螺杆菌 四联疗法 有效性 安全性 

分 类 号：R573[医药卫生—消化系统]